Dr Scott Gerald Story, MD | |
Navy Military Support Cmd: Attn: Medical Staff Services, Bldg H 2005 Knight Lane, Jacksonville, Fl, Fpo, AA 32212-0140 | |
(619) 532-6684 | |
Not Available |
Full Name | Dr Scott Gerald Story |
---|---|
Gender | Male |
Speciality | Radiology - Diagnostic Radiology |
Location | Navy Military Support Cmd: Attn: Medical Staff Services, Fpo, Armed Forces Americas |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487929873 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 01073018A (Indiana) | Secondary |
2085R0202X | Radiology - Diagnostic Radiology | 01073018A (Indiana) | Primary |
Entity Name | Mercy Health Physicians Youngstown Specialty Care Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1649892225 PECOS PAC ID: 3476950296 Enrollment ID: O20210921003835 |
News Archive
Researchers have identified a drug that targets the first step in the toxic chain reaction leading to the death of brain cells, suggesting that treatments could be developed to protect against Alzheimer's disease, in a similar way to how statins are able to reduce the risk of developing heart disease.
"In a letter to leaders of Congress, the secretary of health and human services, Kathleen Sebelius, reported on Monday that the Obama administration is moving quickly to carry out the expansive new health care law, particularly provisions that she referred to as 'early insurance market reforms,'" The New York Times reports.
"In a reflection of the battered economy, the number of people without health insurance rose sharply last year to 50.7 million — an all time high — according to data released Thursday by the Census Bureau" (Kaiser Health News). KHN also provides related resources, including a Census Bureau summary of key findings, the chapter on health insurance coverage and access the full report, "Income, Poverty, and Health Insurance Coverage in the United States: 2009."
Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Scott Gerald Story, MD 11272 Capilla Rd, San Diego, CA 92127-1445 Ph: (808) 397-8067 | Dr Scott Gerald Story, MD Navy Military Support Cmd: Attn: Medical Staff Services, Bldg H 2005 Knight Lane, Jacksonville, Fl, Fpo, AA 32212-0140 Ph: (619) 532-6684 |
News Archive
Researchers have identified a drug that targets the first step in the toxic chain reaction leading to the death of brain cells, suggesting that treatments could be developed to protect against Alzheimer's disease, in a similar way to how statins are able to reduce the risk of developing heart disease.
"In a letter to leaders of Congress, the secretary of health and human services, Kathleen Sebelius, reported on Monday that the Obama administration is moving quickly to carry out the expansive new health care law, particularly provisions that she referred to as 'early insurance market reforms,'" The New York Times reports.
"In a reflection of the battered economy, the number of people without health insurance rose sharply last year to 50.7 million — an all time high — according to data released Thursday by the Census Bureau" (Kaiser Health News). KHN also provides related resources, including a Census Bureau summary of key findings, the chapter on health insurance coverage and access the full report, "Income, Poverty, and Health Insurance Coverage in the United States: 2009."
Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.
› Verified 3 days ago